The Exos@TRM gel builds on the self-assembling RADA16 peptide, adds a TGF-β1-binding peptide and a stem cell-recruiting motif, and releases bone marrow stem cell exosomes for about a week. In rats with surgically made cartilage-and-bone defects, it cut inflammatory M1 macrophages, drew in the animals' own TGF-β1 and stem cells, and formed tissue resembling natural cartilage. The authors note the acute surgical model does not mirror chronic human cartilage wear.
Cosmetics Business published an industry feature in June 2026 cataloging eight peptide-anchored beauty launches during the year's first half, framing 2026 as the year topical peptide skincare crossed from prestige-only to mass-market shelves. Tracked launches include Shiseido's refreshed Ultimune Power Infusing Oil (a serum-format extension of the brand's signature resilience line), YSE Beauty's Xtreme Glow Dewy Peptide Plumping Serum ($68, the company's best first-day and first-week launch by units), and adjacent product categories anchored on PDRN (polydeoxyribonucleotide), exosomes, and acetyl-hexapeptide and palmitoyl-tripeptide blends. AOL and Glossy parallel coverage flagged the K-beauty PDRN-peptide-exosome stack as the defining ingredient combination for 2026 (matched against retinol on efficacy claims, against snail mucin on heritage positioning). The cosmetic-peptide commercial wave runs alongside the regulatory wave: the FDA peptide categories under PCAC review (BPC-157, KPV, TB-500, MOTS-C, Emideltide, Semax, Epitalon) include several with cosmetic-adjacent claims, and the Moes Group / CKYN / GELITA / Italgel manufacturing pipeline tracked in June digests anchors the supply side.